ARCHIVES

Exit Joseph Nevins: Duke’s Genomics Luminary Quietly Leaves

This article is from The Cancer Letter archive.

Vol. 39 No. 39 | October 18, 2013

Download PDF Visit The Full Archive

Related Articles

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

January 13, 2006

Chemo+Radiation Preserves Voice, RTOG Study Finds

December 26, 2003

Cancer Control Contract Negotiations To Start Soon; Two Weaknesses Occur In Many Proposals

March 7, 1975

Senate Finance Reports A Reform Bill On Deadline

July 8, 1994

AVEO’s Tizozanib Fails in Colorectal Cancer

January 10, 2014

Cancer Genome Atlas Reveals Similarities Between Certain Breast and Ovarian Cancers

September 28, 2012